Trial Profile
Phase III clinical study of MN-10-T AI for patients with osteoporosis at higher fracture risk
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 May 2021
Price :
$35
*
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Acronyms MN-10-T-306; TWICE
- Sponsors Asahi Kasei Pharma Corp
- 01 May 2021 Results of a analysis assessing the the effects of baseline lumbar spine bone mineral density (LS-BMD) and bone turnover marker levels on the therapeutic effect published in the Journal of Bone and Mineral Metabolism
- 08 Aug 2019 Primary endpoint (Percentage change in lumbar spine (L2L4) BMD at the final time point) has been met, according to the results published in the Osteoporosis International.
- 08 Aug 2019 Results published in the Osteoporosis International